On 14 November 2024, the JCVI issued further advice regarding a COVID-19 winter 2025 and spring 2026 programmes. In this, they confirmed that as COVID-19 moves to an endemic disease, and as we have used the stocks of vaccine that were bought during the pandemic and are required to purchase more, that the programme should revert to its standard cost effectiveness analysis that it uses for other routine vaccination programmes.